United States
You have no items in your shopping cart.
VDA
Inhibitory Selectivity
| Catalog No. | Inhibitor Name | VDA | Other |
|---|---|---|---|
| A10324 | DMXAA (ASA404, Vadimezan) | ** | |
| A10654 | NPI-2358 (Plinabulin) | *** | |
| A12658 | Verteporfin | YAP/TEAD interaction |
Notes:
1.Hover mouse over "" to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of "" is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
4 Item(s)
per page
| Catalog No. | Product Name | Application | Product Information |
|---|---|---|---|
A10654 SALE |
NPI-2358 (Plinabulin) |
Microtubule Inhibitor |
NPI-2358 is a synthetic analog of NPI-2350, a natural product isolated from Aspergillus sp., which depolymerizes microtubules in A549 human lung carcinoma cells.
|
A10324 SALE |
DMXAA (ASA404, Vadimezan) |
Vascular Disrupting Agent (VDA) |
DMXAA (ASA404) is a tumor-vascular disrupting agent (tumor-VDA) that attacks the blood supply of a cancerous tumor to cause tumor regression.
|
A12658 SALE |
Verteporfin |
YAP inhibitor |
Verteporfin is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin.
|
A14352 |
Oxi 4503 |
VDA |
Oxi4503 is a novel vascular targeting agent that effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
|
4 Item(s)
per page
